These genes have not (yet) been implemented in routine genetic testing strategies for patients with the suspected diagnosis of Gorlin syndrome and might (partially) close the diagnostic gap in young children with SHH-activated medulloblastomas lacking germline PTCH1 or SUFU mutations. This evidence concerns the gene SUFU and nevoid basal cell carcinoma syndrome.